Due to an issue at the manufacturing plant, there is a supply issue affecting the 25 mg and 50 mg strengths of Vedafil brand sildenafil. Sildenafil is funded for a small number of reasons, including ...

Health New Zealand and Pharmac are pleased to announce that from 1 October 2026 the range of funded medicines community pharmacies can provide directly to people in their communities will be expanded ...

The Synthroid and Eltroxin brands of levothyroxine tablets will each be funded in 25 mcg, 50 mcg, 75 mcg, and 100 mcg strengths. A new 75 mcg strength of Synthroid and Eltroxin will be funded for the ...

The Immunisation Advisory Committee also discussed applications in progress for meningococcal, shingles, and RSV vaccines at this meeting. These discussions focused on developing access criteria and ...

details about decisions made for medicines included in the 2025/26 ITT, following the consultations for medicines where Pharmac was considering a possible brand change; and a summary of the feedback ...

Pharmac seeks up to ten people to provide their voice on our Community and Patient Advisory Committee. Members will contribute to discussions on health needs, lived experience, and community ...